Evidence map›Paper›PMID 32630560›Full record

ArticleCancers2020

Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis.

Aleksandr Ianevski, Evgeny Kulesskiy, Klara Krpina, Guofeng Lou, Yahyah Aman, Andrii Bugai, Koit Aasumets, Yevhen Akimov, Daria Bulanova, Kiira Gildemann and 17 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Seven classes of antiviral agents.Cellular and molecular life sciences : CMLS · 2022
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. DNA Damage Response.Biomolecules · 2021
    Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 7 institutions in 6 countries.

Aleksandr IanevskiDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
Evgeny KulesskiyInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, 00014 Helsinki, Finland.
Klara KrpinaDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
Guofeng LouDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway.ORCID 0000-0003-3873-0247
Yahyah AmanDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway.
Andrii BugaiDepartment of Biochemistry and Developmental Biology, University of Helsinki, 00014 Helsinki, Finland.ORCID 0000-0003-1920-6044
Koit AasumetsInstitute of Technology, University of Tartu, 50090 Tartu, Estonia.
Yevhen AkimovInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, 00014 Helsinki, Finland.
Daria BulanovaInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, 00014 Helsinki, Finland.
Kiira GildemannInstitute of Technology, University of Tartu, 50090 Tartu, Estonia.
Albert F ArutyunyanEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Olga Yu SusovaInstitute of Carcinogenesis, FSBI "N.N. Blokhin National Medical Research Center of Oncology", The Ministry of Health of the Russian Federation, 119991 Moscow, Russia.
Alexei L ZhuzeEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Ping JiDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
Wei WangDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
Toril HolienDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.ORCID 0000-0002-2051-5824
Marit BuggeDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
Eva ZusinaiteInstitute of Technology, University of Tartu, 50090 Tartu, Estonia.
Valentyn OksenychDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.ORCID 0000-0002-5088-3791
Hilde LysvandDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
Joachim M GerholdInstitute of Technology, University of Tartu, 50090 Tartu, Estonia.ORCID 0000-0002-4972-1947
Magnar BjøråsDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
Pål JohansenDepartment of Dermatology, University of Zurich, 8006 Zurich, Switzerland.ORCID 0000-0002-5055-6299
Anders WaageDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
Caroline A HeckmanInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, 00014 Helsinki, Finland.ORCID 0000-0002-4324-8706
Evandro F FangDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway.ORCID 0000-0003-0355-7202
Denis E KainovDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
Norwegian University of Science and Technology · NOUniversity of Helsinki · FIUniversity of Tartu · EEUniversity of Oslo · NOEngelhardt Institute of Molecular Biology · RUMinistry of Health · ESUniversity of Zurich · CH

Funding

Estonian Research Competency Council MOBTT39
6 · The paper itself

Abstract

backgroundThe evidence that pan-Bcl-2 or Bcl-xL-specific inhibitors prematurely kill virus-infected or RNA/DNA-transfected cells provides rationale for investigating these apoptotic inducers further. We hypothesized that not only invasive RNA or DNA (biological factors) but also DNA/RNA-damaging chemical or physical factors could trigger apoptosis that have been sensitized with pan-Bcl-2 or Bcl-xL-specific agents; Methods: We tested chemical and physical factors plus Bcl-xL-specific inhibitor A-1155463 in cells of various origins and the small roundworms (

Indexed as

apoptosisBcl-xLnavitoclaxoncolytics

Identifiers

PMID32630560
PMCPMC7352625
OpenAlexW3038038250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.